Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###

###
1. Investment: Eli Lilly is investing an additional $5.3 billion in a manufacturing plant in Lebanon, Indiana, to increase production of diabetes and obesity drugs.
2. Drugs: The plant will produce active pharmaceutical ingredients (APIs) for Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity.
3. Capacity: The investment brings the total outlay to $9 billion, making it the largest synthetic medicine API manufacturing investment in U.S. history.
4. Jobs: The facility will employ 900 workers and create over 5,000 construction jobs.
5. Timeline: Production is expected to begin in 2026 and reach full capacity by 2028.
6. Market: The investment aims to meet the surging demand for GLP-1 drugs, which has led to shortages in the U.S. market.
7. Competitor: Novo Nordisk, a rival company, has also made significant investments to scale up production of its GLP-1 drugs.
8. Government Support: The state of Indiana and the Biden administration have provided support through infrastructure improvements, workforce development, and economic incentives.
9. Revenue: Mounjaro generated $1.8 billion in sales in the first quarter of 2024, while Zepbound accounted for $517 million in sales.
10. Projections: GlobalData predicts that Mounjaro will overtake Novo Nordisk’s Ozempic as the top blood sugar-modulating treatment by 2029.